MFS Special Value Trust (MFV) At $6.18 Forms Top; Radius Health, Inc. (RDUS) Had 6 Analysts Last Week

Among 10 analysts covering Radius Health (NASDAQ:RDUS), 6 have Buy rating, 0 Sell and 4 Hold. Therefore 60% are positive. Radius Health had 27 analyst reports since August 7, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Wednesday, September 21 by H.C. Wainwright. JP Morgan initiated the stock with “Overweight” rating in Friday, October 2 report. Cantor Fitzgerald maintained Radius Health, Inc. (NASDAQ:RDUS) on Sunday, June 4 with “Buy” rating. Jefferies maintained Radius Health, Inc. (NASDAQ:RDUS) rating on Monday, September 4. Jefferies has “Hold” rating and $38.0 target. The firm has “Hold” rating given on Thursday, August 3 by Jefferies. As per Thursday, September 24, the company rating was maintained by Canaccord Genuity. The stock has “Buy” rating by H.C. Wainwright on Friday, March 24. The firm has “Outperform” rating given on Friday, May 6 by Cowen & Co. Deutsche Bank initiated the stock with “Buy” rating in Friday, August 14 report. The firm has “Buy” rating by Canaccord Genuity given on Monday, June 5. See Radius Health, Inc. (NASDAQ:RDUS) latest ratings:

08/12/2017 Broker: Cowen & Co Rating: Hold
06/12/2017 Broker: Citigroup Rating: Hold New Target: $30.0 Initiate
02/11/2017 Broker: Jefferies Rating: Hold New Target: $31.0 Maintain
10/10/2017 Broker: Jefferies Rating: Hold New Target: $38.0 Maintain
25/09/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $58.0 Maintain
04/09/2017 Broker: Jefferies Rating: Hold New Target: $38.0 Maintain
03/08/2017 Broker: Jefferies Rating: Hold New Target: $38.0000 Maintain
23/07/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $58.0000 Maintain
13/07/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $65.0000 Maintain

MFS Special Value Trust (MFV) formed multiple top with $6.61 target or 7.00% above today’s $6.18 share price. MFS Special Value Trust (MFV) has $43.86M valuation. The stock decreased 2.68% or $0.17 during the last trading session, reaching $6.18. About 83,459 shares traded or 450.85% up from the average. MFS Special Value Trust (NYSE:MFV) has risen 14.42% since December 25, 2016 and is uptrending. It has underperformed by 2.28% the S&P500.

Radius Health, Inc., a biopharmaceutical company, develops and sells therapeutics in the areas of osteoporosis, oncology, and endocrine diseases primarily in the United States. The company has market cap of $1.38 billion. The Company’s product candidates include Abaloparatide-SC, an injectable subcutaneous formulation of abaloparatide, which has completed Phase III clinical trial for the treatment of patients with postmenopausal osteoporosis; and Abaloparatide-TD, a transdermal patch for use as a short wear-time transdermal patch. It currently has negative earnings. The firm is also involved in developing RAD1901, a selective estrogen receptor down-regulator/degrader, which is in Phase I clinical trial for the treatment of metastatic breast cancer, as well as in Phase IIb clinical trial for the treatment of postmenopausal vasomotor symptoms; and RAD140, a nonsteroidal selective androgen receptor modulator for the treatment of breast cancer.

Since August 9, 2017, it had 6 insider buys, and 0 insider sales for $17.58 million activity. 50,000 shares were bought by BIOTECH GROWTH N V, worth $1.77M on Tuesday, September 12.